Top Markets
#1 Pleasing Gold Pleasing Gold +1,501.46%
#2 Ontology Gas Ontology Gas +131.75%
#3 PulseChain PulseChain +61.85%
#4 Osmosis Osmosis +35.55%
#5 BOOK OF MEME BOOK OF MEME +31.03%
#6 Ontology Ontology +30.60%
#7 Neiro Neiro +30.07%
#8 Collect on Fanable Collect on Fanable +28.80%
#9 Unit Pump Unit Pump +28.63%
#10 Pump.fun Pump.fun +28.63%
Coin of the day
Pleasing Gold Pleasing Gold
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
LAVA Therapeutics N.V. LAVA Therapeutics N.V.

LAVA Therapeutics N.V.

LVTX
Peringkat dalam Saham #25846
LAVA Therapeutics N.V. is an immuno-oncology firm, currently in the clinical... LAVA Therapeutics N.V. is an immuno-oncology firm, currently in the clinical development phase, dedicated to pioneering novel therapies for cancer. Utilizing its proprietary Gammabody platform, the company engineers innovative bispecific antibodies. These antibodies are specifically designed to engage and harness the potent and precise capabilities of gamma delta T cells, aiming to stimulate a robust anti-tumor immune response and ultimately enhance outcomes for individuals battling cancer. Key compounds in its clinical pipeline include LAVA-051, currently undergoing Phase 1/2a trials for various hematologic malignancies such as chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. Another front-runner, LAVA-1207, is also in Phase 1/2a clinical studies, targeting metastatic castration-resistant prostate cancer. Furthermore, LAVA Therapeutics is advancing additional Gammabody candidates: LAVA-1223, an investigational treatment for specific solid tumors that targets the epidermal growth factor receptor (EGFR), and preclinical assets LAVA-1266 and LAVA-1278, intended for a range of blood cancers. The company has also forged a research collaboration and licensing partnership with Janssen Biotech, Inc. This alliance focuses on the potential discovery and development of multi-specific antibody therapies aimed at a particular target across diverse therapeutic applications. Established in 2016, LAVA Therapeutics N.V. operates from its headquarters in Utrecht, the Netherlands.
Harga Saham
$1.74
Terakhir disinkronkan: 2025-11-28
Kapitalisasi Pasar
$45.77M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
13.73%
Negara
NL
Perdagangan LAVA Therapeutics N.V. (LVTX)

Kategori

Healthcare
Riwayat dividen untuk LAVA Therapeutics N.V. (LVTX)
Saham LAVA Therapeutics N.V. (simbol: LVTX) telah membayar total 0 dividen.
Total semua dividen (disesuaikan dengan stock split): 0.00
Imbal hasil dividen (TTM): 0
Pembayaran dividen untuk LAVA Therapeutics N.V. (LVTX) dari 2026 hingga 2026
Pembayaran dividen tahunan
Tahun Dividen (disesuaikan dengan stock split) Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Daftar semua pembayaran dividen
Tahun Dividen Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Pembayaran dividen untuk perusahaan sejenis atau pesaing
Perusahaan Jumlah pembayaran dividen Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US